| (Values in U.S. Thousands) | Dec, 2025 | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 |
| Sales | 0 | 0 | 430 | 1,300 | 1,540 |
| Sales Growth | unch | -100.00% | -66.92% | -15.58% | +69.23% |
| Net Income | -1,360 | -4,270 | -2,820 | -9,800 | -25,050 |
| Net Income Growth | +68.15% | -51.42% | +71.22% | +60.88% | -454.31% |
Aptorum Group Ltd Cl A (APM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Aptorum Group Limited is a pharmaceutical company. It engaged in developing and commercializing therapeutic and diagnostic technologies to tackle unmet medical needs. The company's therapeutic and diagnostic project primarily includes neurology, infectious diseases, gastroenterology, oncology and other disease areas. Aptorum Group Limited is based in Connaught Road, Hong Kong.
Fiscal Year End Date: 12/31